PNC 27: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

PNC-27 (CAS 1159861-00-3) is a 35-amino-acid chimeric peptide that fuses the HDM-2-binding domain of the tumor suppressor p53 (residues 12-26) with a membrane-residence peptide derived from penetratin. In research models its capacity to induce cell death by pore formation in the membrane of tumor cells has been explored. Its evidence is primarily preclinical.

PNC-27 is a synthetic chimeric peptide designed as a research tool in experimental oncology. Its name comes from "Peptide, Novel, Cancer" and, within the catalog, it belongs to the category of compounds of interest in anti-aging and senescence due to its relationship with the p53 tumor suppressor pathway, although its literature focuses above all on the study of the selective death of transformed cells. It is a well-defined molecule: molecular formula C188H293N53O44S, approximate molecular weight of 4031.8 g/mol and CAS number 1159861-00-3. In the literature it also appears under the description of "p53-penetratin chimeric peptide".

Structurally, PNC-27 combines two functional modules in a single 35-amino-acid chain. The first module corresponds to residues 12-26 of the p53 protein, the region that in the full protein makes contact with HDM-2 (the human counterpart of MDM-2), the negative regulator that marks p53 for degradation. The second module is a membrane penetration/residence peptide derived from the homeodomain of Antennapedia (penetratin), which provides the capacity to associate with lipid bilayers and internalize into cells. The presence of a single sulfur atom in the formula is consistent with a single methionine in the penetratin segment. The fusion of a molecular recognition domain with a membrane transport domain is the design principle that distinguishes this class of "dual-domain" chimeric peptides.

As for the mechanism of action proposed in preclinical models, PNC-27 departs from the classical mechanism expected for a p53 fragment. The dominant hypothesis in the literature of its developers is that HDM-2 not only resides in the nucleus and cytoplasm, but that in cancer cells it is also expressed in the plasma membrane. According to this model, PNC-27 would recognize the membrane-associated HDM-2 of tumor cells; once anchored by its p53 domain and stabilized by its penetratin domain, the peptide would participate in the formation of transmembrane pores or channels that compromise the integrity of the bilayer. The result observed in culture is cell death with characteristics of necrosis (membrane permeabilization, release of cytoplasmic content) rather than of apoptosis dependent on the canonical p53 cascade. A point emphasized in that line of work is the apparent selectivity: in the systems studied, non-transformed cells, which would express little or no HDM-2 in their membrane, showed greater tolerance than tumor cells. It is important to note that this membrane mechanism, although internally consistent and supported by the group that developed the compound, does not enjoy the same degree of independent validation as the mechanisms of approved drugs, and must be treated as a working hypothesis within a strictly experimental context.

The documented research applications lie in the field of cancer biology and of the p53-HDM-2/MDM-2 interaction. PNC-27 has been used as a probe to study the membrane localization of HDM-2 in different cell lines, as an agent to explore mechanisms of selective cytotoxicity based on pore formation, and as a model of a "dual-domain chimeric peptide" for the rational design of targeted molecules. In culture systems it has been tested on various types of tumor cells (for example, lines derived from solid and hematological cancers) to characterize its range of activity, and its control analog PNC-28 and related peptides have also been used to dissect which segments of the sequence are responsible for the observed activity. Its interest for the longevity and senescence category derives from the fact that the p53-MDM-2 pathway is central to the regulation of the cell cycle, senescence, and the elimination of damaged cells, so PNC-27 serves as a conceptual tool to study that pathway, although not as a compound with lifespan-extension data.

The level of evidence must be presented honestly. PNC-27 is a research compound whose data set comes fundamentally from in vitro studies and some animal models, in large part generated by the academic group that originally described it. There are no clinical trials supporting a therapeutic use, and it is not approved by any regulatory agency. Independent evidence and replication by external groups are limited compared with established pharmacological classes. For this reason, any interpretation of its results should be confined to the domain of basic and preclinical research, and claims about tumor selectivity or efficacy should be considered preliminary and pending further validation.

In summary, PNC-27 is a chimeric peptide of well-characterized molecular identity that integrates the p53(12-26) HDM-2-binding domain with a penetratin module, designed to study the selective death of tumor cells through an HDM-2-mediated membrane-permeabilization mechanism. It constitutes a useful tool for research on the p53-MDM-2 pathway and on the design of membrane-targeted peptides, always within an experimental framework and with the caveat that its evidence is predominantly preclinical and still in the process of independent consolidation.